These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19634927

  • 1. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF, Siddiqui MA.
    Drugs; 2009 Jul 30; 69(11):1513-32. PubMed ID: 19634927
    [Abstract] [Full Text] [Related]

  • 2. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2457-89. PubMed ID: 22141388
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 4. [Etoricoxib (Arcoxia)].
    Leclercq P, Malaise MG.
    Rev Med Liege; 2004 May 18; 59(5):345-9. PubMed ID: 15270001
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS.
    Curr Pharm Des; 2007 May 18; 13(22):2228-36. PubMed ID: 17691996
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr 18; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W.
    Pharmacoeconomics; 2010 Apr 18; 28(4):323-44. PubMed ID: 20222755
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S.
    Pharmacoeconomics; 2004 Apr 18; 22(10):643-60. PubMed ID: 15244490
    [Abstract] [Full Text] [Related]

  • 10. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 11. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
    Curr Med Res Opin; 2004 Dec 10; 20(12):1899-908. PubMed ID: 15701208
    [Abstract] [Full Text] [Related]

  • 12. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S, Klotz U.
    Eur J Clin Pharmacol; 2008 Mar 10; 64(3):233-52. PubMed ID: 17999057
    [Abstract] [Full Text] [Related]

  • 13. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
    Patrignani P, Capone ML, Tacconelli S.
    Expert Opin Pharmacother; 2003 Feb 10; 4(2):265-84. PubMed ID: 12562317
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 10; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 15. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC.
    Curr Top Med Chem; 2005 Aug 10; 5(5):443-8. PubMed ID: 15974939
    [Abstract] [Full Text] [Related]

  • 16. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 10; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 17. A case report on toxic epidermal necrolysis with etoricoxib.
    Kameshwari JS, Devde R.
    Indian J Pharmacol; 2015 Dec 10; 47(2):221-3. PubMed ID: 25878388
    [Abstract] [Full Text] [Related]

  • 18. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 10; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.